Practical guidelines for dose individualization of anticancer targeted drugs

Area of Science:

• Oncology
• Pharmacology
• Nephrology
• Hepatology

Background:

• Anticancer agents require dose individualization to manage toxicity and optimize therapeutic benefit.
• Renal and hepatic function significantly impact the elimination of many anticancer drugs.
• Optimal starting doses for antineoplastic agents in patients with organ dysfunction are not well-established.

Purpose of the Study:

• To review trials assessing dosing strategies for new targeted anticancer agents in patients with renal or hepatic dysfunction.
• To provide practical guidelines for dose individualization of monoclonal antibodies and tyrosine kinase inhibitors.

Main Methods:

• Literature review of clinical trials evaluating targeted anticancer agents.
• Analysis of dosing strategies in patients with overt biochemical renal and liver dysfunction.

Main Results:

• Discusses specific dosing strategies for targeted agents like monoclonal antibodies and tyrosine kinase inhibitors.
• Highlights the importance of considering renal and liver function for safe and effective dosing.

Conclusions:

• Dose individualization based on renal and liver function is essential for targeted anticancer therapies.
• Recommendations and practical guidelines are provided for clinicians to manage dosing in patients with organ dysfunction.